• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD.

作者信息

De Arka, Bhagat Naveen, Mehta Manu, Taneja Sunil, Duseja Ajay

机构信息

Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

出版信息

J Hepatol. 2024 Feb;80(2):e61-e62. doi: 10.1016/j.jhep.2023.07.031. Epub 2023 Aug 7.

DOI:10.1016/j.jhep.2023.07.031
PMID:37558135
Abstract
摘要

相似文献

1
Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD.对于非酒精性脂肪性肝病（NAFLD）的瘦患者，代谢功能障碍相关脂肪性肝病（MASLD）的定义优于代谢功能障碍相关脂肪性肝病（MAFLD）标准。
J Hepatol. 2024 Feb;80(2):e61-e62. doi: 10.1016/j.jhep.2023.07.031. Epub 2023 Aug 7.
2
Steatotic liver disease, MASLD and risk of chronic kidney disease.脂肪性肝病、MASLD 和慢性肾脏病风险。
Diabetes Metab. 2024 Jan;50(1):101506. doi: 10.1016/j.diabet.2023.101506. Epub 2023 Dec 21.
3
Why MASLD Lags Behind MAFLD: A Critical Analysis of Diagnostic Criteria Evolution in Metabolic Dysfunction-Associated Liver Diseases.为什么 MASLD 落后于 MAFLD：代谢相关脂肪性肝病相关诊断标准演变的批判性分析。
Med Sci Monit. 2024 Jul 30;30:e945198. doi: 10.12659/MSM.945198.
4
Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions.代谢相关性脂肪性肝病/代谢相关脂肪性肝病的管理：从药物治疗到营养干预。
Nutrients. 2024 Jul 11;16(14):2220. doi: 10.3390/nu16142220.
5
Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.脂肪性肝病新命名法的意义及代谢相关脂肪性肝病的定义。
Aliment Pharmacol Ther. 2024 Jan;59(2):150-156. doi: 10.1111/apt.17846.
6
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.代谢相关脂肪性肝病和非酒精性脂肪性肝病的临床特征和病死率相似。
J Hepatol. 2024 May;80(5):694-701. doi: 10.1016/j.jhep.2024.01.014. Epub 2024 Jan 27.
7
Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.慢性肾脏病发生时代谢功能障碍相关脂肪/脂肪变性肝病的严重程度和缓解情况。
J Am Heart Assoc. 2024 Mar 5;13(5):e032604. doi: 10.1161/JAHA.123.032604. Epub 2024 Feb 23.
8
Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?开辟新天地：代谢功能障碍相关脂肪性肝病（MASLD）与代谢功能障碍相关脂肪性肝炎（MAFLD）——哪一个是风险分层的关键？
Hepatol Int. 2024 Feb;18(1):168-178. doi: 10.1007/s12072-023-10620-y. Epub 2023 Dec 21.
9
[Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features].基于临床特征分析非酒精性脂肪性肝病与代谢功能障碍相关脂肪性肝病的差异
Zhonghua Gan Zang Bing Za Zhi. 2024 Apr 20;32(4):346-353. doi: 10.3760/cma.j.cn501113-20231022-00153.
10
Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults.美国成年人中NAFLD、MAFLD和MASLD的特征及死亡率结果比较。
Liver Int. 2024 Apr;44(4):1051-1060. doi: 10.1111/liv.15856. Epub 2024 Jan 31.

引用本文的文献

1
Myths and facts about the role of diet in metabolic dysfunction-associated steatotic liver disease.关于饮食在代谢功能障碍相关脂肪性肝病中作用的误解与事实
World J Hepatol. 2025 Aug 27;17(8):107909. doi: 10.4254/wjh.v17.i8.107909.
2
Downregulation of ubiquitous microRNA-320 in hepatocytes triggers RFX1-mediated FGF1 suppression to accelerate MASH progression.肝细胞中普遍存在的微小RNA-320的下调触发了RFX1介导的FGF1抑制，从而加速MASH进展。
Acta Pharm Sin B. 2025 Aug;15(8):4096-4114. doi: 10.1016/j.apsb.2025.06.007. Epub 2025 Jun 9.
3
Narrative review of metabolic syndrome and its relationships with non-alcoholic fatty liver disease, gonadal dysfunction and obstructive sleep apnea.
代谢综合征及其与非酒精性脂肪性肝病、性腺功能障碍和阻塞性睡眠呼吸暂停关系的叙述性综述
Diabetol Metab Syndr. 2025 Aug 25;17(1):353. doi: 10.1186/s13098-025-01903-5.
4
Increased BMD in SLD Patients Without Advanced Hepatic Fibrosis: Evidence From the NHANES 2017-2020 Database.无晚期肝纤维化的非酒精性脂肪性肝病患者骨密度增加：来自2017 - 2020年美国国家健康与营养检查调查数据库的证据
Can J Gastroenterol Hepatol. 2025 Aug 11;2025:6969761. doi: 10.1155/cjgh/6969761. eCollection 2025.
5
Liver stiffness measurements in patients with metabolic dysfunction-associated steatotic liver disease: Updates on the method effectiveness and perspectives.代谢功能障碍相关脂肪性肝病患者的肝脏硬度测量：方法有效性及前景的最新进展
World J Hepatol. 2025 Jul 27;17(7):106675. doi: 10.4254/wjh.v17.i7.106675.
6
Immune Microenvironment on the Molecular Mechanisms and Therapeutic Targets of MAFLD.免疫微环境对MAFLD分子机制及治疗靶点的影响
Immunotargets Ther. 2025 Jul 11;14:719-733. doi: 10.2147/ITT.S530451. eCollection 2025.
7
The impact of BCLC recommendations on survival for patients with hepatocellular carcinoma.巴塞罗那临床肝癌（BCLC）分期推荐对肝细胞癌患者生存率的影响。
Hepatol Commun. 2025 Jul 14;9(8). doi: 10.1097/HC9.0000000000000750. eCollection 2025 Aug 1.
8
Rhein alleviates hepatic steatosis in NAFLD mice by activating the AMPK/ACC/SREBP1 pathway to enhance lipid metabolism.大黄酸通过激活AMPK/ACC/SREBP1通路增强脂质代谢，从而减轻非酒精性脂肪性肝病（NAFLD）小鼠的肝脂肪变性。
Mol Med. 2025 Jul 10;31(1):255. doi: 10.1186/s10020-025-01304-4.
9
Gut microbiota modulation by Traditional Chinese Medicine: a translational strategy for metabolic dysfunction-associated steatotic liver disease.中药对肠道微生物群的调节作用：代谢功能障碍相关脂肪性肝病的转化策略
Front Pharmacol. 2025 Jun 10;16:1600439. doi: 10.3389/fphar.2025.1600439. eCollection 2025.
10
Adoption of the New Nomenclature of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by the Indian National Association for Study of the Liver (INASL): Implications for the INASL Guidance Paper on NAFLD.印度国家肝脏研究协会（INASL）采用代谢功能障碍相关脂肪性肝病（MASLD）新命名法：对INASL非酒精性脂肪性肝病指南文件的影响
J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102590. doi: 10.1016/j.jceh.2025.102590. Epub 2025 May 16.